NEW YORK (GenomeWeb News) – Affymetrix today reported preliminary revenues of approximately $91 million for the fourth quarter of 2013, which would beat the consensus analyst estimate of $82.6 million.

The preliminary figure for the quarter would be an 8 percent increase over the $84.3 million the Santa Clara, Calif.-based firm posted in revenues for the fourth quarter of 2012 and includes a one-time licensing payment of $5.3 million from an unnamed diagnostic partner.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.